


Interim Results Presentation

For the six months ended 30th June 2007

Disclaimer

- This presentation does not constitute an offer to sell or a solicitation of offers to buy Ordinary Shares (the “Securities”). Although reasonable care has been taken to ensure that the facts stated in this presentation are accurate and that the opinions expressed are fair and reasonable, the contents of this presentation have not been verified by Plethora Solutions Holdings plc (the “Company”) or any other person. Accordingly, no representation or warranty, express or implied, is made as to the fairness, accuracy, completeness or correctness of the information and opinions contained in this presentation, and no reliance should be placed on such information or opinions. Further, the information in this presentation is not complete and may be changed. Neither the Company nor any of its respective members, directors, officers or employees nor any other person accepts any liability whatsoever for any loss howsoever arising from any use of such information or opinions or otherwise arising in connection with this presentation.
- This presentation may contain forward-looking statements that reflect the Company's current expectations regarding future events, its liquidity and results of operations and its future working capital requirements and capital raising activities. Forward-looking statements involve risks and uncertainties. Actual events could differ materially from those projected herein and depend on a number of factors, including the success of the Company's development strategies, the successful and timely completion of clinical studies, the ability of the Company to obtain additional financing for its operations and the market conditions affecting the availability and terms of such financing.

Building a Sustainable Urology Company



H1 2007 Highlights

Product Revenues

- Revenues of £2.8m (H1 2006 £2.4m)
- Gross profit of 86% (H1 2006: 77%)

Licensing

- **PSD502**: Sciele licensing agreement for the USA
- Co-Promotion rights retained for the USA
- Non-US rights in negotiation
- **PSD597**: Phase II data enables licensing discussions to begin

Development


- **PSD502**: Completion of US IND study
- **PSD597**: Completion of Phase II study
- **PSD510**: Clearance from FDA to proceed to pivotal study

Product Revenues

- H1 Timm Medical sales of £2.8m (H1 2006 £2.4m)
- Gross margin improvement to 86% from 77% driven by relocation of component manufacture to China
- Sales force expanded
- Continued increase in ErecAid sales to post radical prostatectomy patients
- Initiated marketing programme for failed medical management e.g. diabetes patients
- Expanded portfolio through acquisition of US rights to 2 new urology consumable products – Acticuf and Cleancatch

Licensing

- Exclusive agreement with Sciele Pharma Inc reached for US rights delivering significant value to Plethora
 - \$7m equity investment indicates value beyond PSD502
 - Regulatory and sales milestones
 - Royalties on Sales
- Plethora has retained full co-promotion rights for PSD502 to urologists
- Ex-US PSD502 PE licensing discussions ongoing
- Licensing discussions for PSD502 in wound pain progressing
- Discussions beginning for PSD597 in IC/PBS following successful Phase II trial data




Development Update: Driving Value

Male Health Franchise

Product	Indication	Category	Status	Potential Launch
ErecAid	ED	Device	Marketed	Launched
PSD502	PE	Therapeutic	Phase III	2009
PSD510 'Invicorp'	ED	Therapeutic	Phase II/III	2009

PSD502: Progress to Phase III

- Safe and effective metered aerosol delivery with fast onset of action to treat PE
- Phase II completed successfully
- US IND opened with pK study, completed in 06.07 confirming safety and tolerability
- Positive meetings with US and European regulators confirmed Phase III protocol - programme will comprise two x 270 patient studies
- Phase III scheduled to begin in Q4 07
- Manufacturing agreement in place




PSD510: Invicorp[®] for Erectile Dysfunction

- Product Injectable drug for patients refractory or contra-indicated for oral ED medication
- Rights Exclusive North American rights
- Benefits Effective within 2.5 minutes for approx. 1 hour, safe, no pain/bleeding at injection site

	Caverject [®] Impulse	MUSE [®]	Invicorp [®]
Pain	37%	32% (penile) 12% (urethral)	0% in 2 studies (~6000 injections), 11% one study

- Status Phase III in the US, IND opened in the US, positive outcome to FDA meeting
- Market Initial patient pool of 2.6m men in the USA

Male Health Franchise Driving Value



- Sciele and future OUS agreements contribute milestones and royalties
- Product sales driven through Timm Medical

Women's Health Franchise


Product	Indication	Description	Status
PSD597	Interstitial cystitis	Therapeutic	Phase II
PSD503	SUI	Therapeutic	Phase II
PSD506	OAB (LUTS)	Therapeutic	Phase II
PSD508	Dysmenorrhea	Therapeutic	Phase II
PSD509	Uterine pain	Therapeutic	Pre Phase II

PSD597: Treatment for Interstitial Cystitis

- **Product:** Novel therapy for the treatment of interstitial cystitis/painful bladder syndrome (IC/PBS).
- **Market Potential:** Estimates of IC/PBS prevalence in adult women* range report a patient population of 6 million sufferers in the USA alone
- **Competition** Limited and ineffective therapeutic options
- **Status:** Multi-centre Phase II, data reported 09.2007
- **Study:** Reduction in IC symptoms, improved QoL, pain relief, safety, duration of action
- **Pre-clinical:** Pre-clinical programme investigating utility of novel micelle technology to report in Q4 2007

*: Datamonitor, 2006


PSD597 Phase II IC/PBS study



- Enrolled subjects: 102
- PSD597: 50; Placebo: 52
- Completed double-blind: 95
- Discontinued during double-blind: 7
- Electing to start open-label treatment: 82

PSD597: Phase II Outcome

- Primary endpoint: Global Response Assessment (GRA) – a well recognised measure of response in IC; becoming standard outcome measure
- Significantly greater GRA score and clinical improvement in all subjects with PSD597 over placebo at Day 15 ($p=0.005$)
- Significant improvement in marked to moderate responders at Day 8 and Day 15
 - Day 8: 30% on PSD597 vs 10% on placebo ($p=0.012$)
 - Day 15: 24% on PSD597 vs 12% on placebo
- 2° endpoints - Symptomatic endpoints; Pharmacokinetics
- Full data to be reported later in the year



Phase II Women's Health Products

- **PSD503:** Topical formulation of an alpha-agonist for on-demand treatment of mild to moderate stress urinary incontinence

- Benefits: Dryness, decreased reliance on incontinence pads, safe

- Status: Multi-centre Phase II reporting 2007

- **PSD506:** Oral anti-muscarinic for the treatment of overactive bladder (OAB) in woman and lower urinary tract symptoms (LUTS) which arise from BPH in men

- Benefits: Benign safety profile, reduced urinary urgency and convenient dosing

- Status: Phase II studies reporting in 2007

- **PSD508:** Intra-vaginal delivery of NSAID for the treatment of dysmenorrhea

- Benefits: Rapid relief from menstrual pain, dosing on-demand, benign safety profile


- Status: Phase II to be initiated late 2007

H1 2007: Consolidated P&L

	Six Months to 30 June 2007* £'000s	Six Months to 30 June 2006* £'000s	Year to 31 December 2006 £'000s
Revenues	2,783	2,406	5,158
Cost of Goods	390	562	1,071
Gross Profit	2,393	1,844	4,087
Central & General	1,377	847	1,632
Sales & Marketing	2,044	1,358	3,127
Development	3,586	1,669	5,402
Amortisation of intangibles	232	186	418
Total Operating Costs	7,239	4,060	10,579
Profit /(Loss) on Operations	(4,846)	(2,216)	(6,492)
Finance income/(cost)	24	137	253
Tax	46	56	344
Net Profit /(Loss)	(4,776)	(2,023)	(5,895)

* unaudited accounts

Current Clinical Development Pipeline



H1 07: Consolidated Summarised Balance Sheet & Cash Flow

	At 30 June 2007* £000s	At 30 June 2006* £000s	At 31 December 2006 £000s
Non current Assets	6,454	7,355	6,706
Cash	7,507	6,573	3,439
Other current assets	983	1,161	1,319
Current liabilities	(3,213)	(1,606)	(2,027)
Non current liabilities	(4,602)	(2,281)	(2,068)
Net assets	7,129	11,202	7,369
Net cash from operating activities	(4,069)	(2,009)	(5,206)
Net cash from investing activities	34	(4,922)	(4,863)
Cash outflow before financing	(4,035)	(6,931)	(10,069)
Net cash inflow from financing	8,103	7,291	7,295
Increase in cash	4,068	360	(2,774)


* unaudited accounts

Business Drivers 2007/8

Indication	Product	Development	Commercial [*]
ED	ErecAid [®]		Revenues/new products
	Invicorp [®]	Phase III	NA Partner potential
PE	PSD502	Phase III	Partnering
	PSD502(W)		Partnering
UI	PSD503	Clinical data	
	PSD506	Clinical data	
Women's Health	PSD597	Clinical data	Partnering
	PSD508/509	Clinical data	

* Company forecast subject to satisfactory and timely completion of clinical trials

Plethora Solutions Investment Proposition



- Commercially driven, validated business model
- Profitable US business sales & marketing business
- 6 proprietary Phase II/III products
- Significant commercial and clinical news-flow in 2007/8
- Significant growth potential
- Market cap of £33m